Taumedis is a pre-commercialization medical imaging start-up developing multi-modality intraoperative imaging solutions, bringing high-quality imaging to the patient while integrating into the surgical workflow.

Formed in 2018—and officially founded in 2023—by a group of Canadian scientists and engineers passionate about medical imaging, the name Taumedis is an acronym for tau Medical Imaging Solutions, where the Greek letter tau (τ) has significance in both magnetic resonance imaging as well as a variety of neurodegenerative diseases. With over 70 years of collective experience in the medical imaging field, the Taumedis team strives to develop the highest quality medical imaging solutions to hospitals, clinics, and research facilities.

Winnipeg, Manitoba is home to Taumedis, strategically located at the geographic center of North America. Winnipeg has a rich heritage of medical imaging R&D going back to the National Research Council Institute for Biodiagnostics (NRC-IBD), a research laboratory established in 1992 that aimed to investigate and develop non-invasive medical diagnostic technology for the prevention, early diagnosis, and improved treatment and prognosis of diseases. The NRC-IBD focused on areas of magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and infrared spectroscopy (IRS), spawning a variety of technological innovations that stood at the forefront of their respective modalities.